DariaRen
Bausch Health Companies' (NYSE:BHC) Solta Medical portion has withdrawn its exertion to rise up to $100M done a US archetypal nationalist offering.
Solta filed its IPO exertion successful February. While the filing didn't specify the fig and pricing of the shares to beryllium offered, an attached filing interest schedule indicated the institution was looking to rise astir $100M, a fig that was apt a placeholder and taxable to change.
Solta wasn't going to person immoderate currency from the deal, with proceeds slated to spell to its parent, Bausch Health. Solta is Bausch's aesthetic aesculapian devices unit, processing and selling products for procedures specified arsenic assemblage contouring, tegument tightening and tegument resurfacing.
The Solta spinout would've been Bausch's 2nd this year. The healthcare conglomerate held an IPO for its eyecare portion Bausch + Lomb (BLCO) successful May, raising $630M.
/cdn.vox-cdn.com/uploads/chorus_asset/file/24020034/226270_iPHONE_14_PHO_akrales_0595.jpg)
English (US)